Revenue Breakdown
Composition ()
No data
Revenue Streams
Galapagos NV (GLPG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is R&D, accounting for 96.7% of total sales, equivalent to €127.52M. Another important revenue stream is Fee-for-services. Understanding this composition is critical for investors evaluating how GLPG navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Galapagos NV maintains a gross margin of 99.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 86.65%, while the net margin is 86.86%. These profitability ratios, combined with a Return on Equity (ROE) of 10.42%, provide a clear picture of how effectively GLPG converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GLPG competes directly with industry leaders such as AUPH and RXRX. With a market capitalization of $2.25B, it holds a leading position in the sector. When comparing efficiency, GLPG's gross margin of 99.95% stands against AUPH's 88.59% and RXRX's 59.83%. Such benchmarking helps identify whether Galapagos NV is trading at a premium or discount relative to its financial performance.
